Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
November 12 2024 - 6:54AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of November 2024
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca invests $3.5 billion in US
12 November 2024
AstraZeneca invests $3.5 billion
in R&D and manufacturing in the United States
AstraZeneca today announces $3.5 billion of capital investment in
the United States focused on expanding the Company's research and
manufacturing footprint by the end of 2026. This includes $2
billion of new investment creating more than a thousand new,
high-skilled jobs contributing to the growth of the US
economy.
AstraZeneca's expanding footprint in the US includes, among
others:
● A
state-of-the-art R&D centre in Kendall Square, Cambridge,
Massachusetts
● A
next generation manufacturing facility for biologics in
Maryland
● Cell
therapy manufacturing capacity on the West and East
Coasts
● Specialty
manufacturing in Texas
Pascal Soriot, Chief Executive Officer, AstraZeneca said:
"Our
multibillion dollar investment reflects the attractiveness of the
business environment together with the quality of talent and
innovation capabilities here in the United States. By expanding our
R&D and manufacturing footprint, we aim to enhance the
development of cutting-edge therapies and support the United States
leadership in healthcare innovation."
Delivering growth: Ambition 2030
These US investments are the first of a series of important steps
to help deliver AstraZeneca's ambition to achieve $80 billion in
Total Revenue by 2030 as set out in May this
year. A key element of our strategy is
accelerating the Company's development in the United States. The US
is AstraZeneca's largest market, generating 44% of its Total
Revenue.1
AstraZeneca in the US
AstraZeneca has approximately 17,800 employees working across 17
R&D, manufacturing and commercial sites spanning 12
states.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
References
1. As at
Q3 2024 noted in AstraZeneca Q3 Financial Results. Available
at: https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html.
Accessed November 2024.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
12 November 2024
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Oct 2024 to Nov 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Nov 2023 to Nov 2024
